Fig. 6: Enhanced delivery of liposomal DOX and aPD-1 by LIPU/MB increases survival in GBM-bearing mice. | Nature Communications

Fig. 6: Enhanced delivery of liposomal DOX and aPD-1 by LIPU/MB increases survival in GBM-bearing mice.

From: Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas

Fig. 6

a Therapeutic scheme employed to treat GBM-bearing mice with the combination of liposomal DOX and aPD-1 delivered with or without LIPU/MB using GL261 and CT-2A cells. b Kaplan-Meier curves showing the survival of GL261-bearing mice treated with aPD-1, liposomal DOX (n = 7 mice per group), and the tumor rechallenge experiment performed in long-term survivors (n = 5 mice for the control group, n = 2 mice for DOX group, n = 3 mice for DOX+aPD-1 group). c Kaplan-Meier curves showing the survival of GL261-bearing mice treated with aPD-1, liposomal DOX with LIPU/MB (n = 7 mice for control, aPD-1, and DOX groups, n = 8 mice for DOX + LIPU/MB and DOX+aPD-1 + LIPU/MB groups), and the tumor rechallenge experiment performed in long-term survivors (n = 5 mice for the control group, n = 2 mice for DOX group, n = 6 mice for both DOX + LIPU/MB and DOX+aPD-1 + LIPU/MB groups). d Kaplan-Meier curve showing survival of CT-2A-bearing mice treated with aPD-1, the combinatorial therapy with and without LIPU/MB (n = 10 mice for the control group, n = 9 for aPD-1 group, n = 8 mice for DOX+aPD-1 group, n = 10 for DOX group, n = 8 mice for DOX + LIPU/MB group, and n = 10 mice for DOX+aPD-1 + LIPU/MB group). e Therapeutic scheme employed following myeloid cell depletion using PLX3397 in GBM-bearing mice with the combination of liposomal DOX and aPD-1 delivered with LIPU/MB using CT-2A cells. f Kaplan-Meier curve showing the survival of CT-2A-bearing mice treated with either control diet or PLX3397 followed by liposomal DOX, aPD-1, and LIPU/MB (n = 8 mice for the control diet group, n = 6 mice for the PLX3397 group). g Kaplan-Meier curve showing the survival of newly injected mice with CT-2A, and long-term survivors treated with either the control diet or PLX3387 (n = 7 mice for the control diet group, n = 7 mice for the PLX3397 group, n = 3 mice for the control diet DOX+aPD-1 + LIPU/MB group, n = 4 mice for the PLX3397 DOX+aPD-1 + LIPU/MB group). P values in b–d, f and g were derived from the log-rank test. Source data are provided as a Source Data file.

Back to article page